go-flag: bridge therapy to allo-sct in r/r aml
Published 4 years ago • 87 plays • Length 0:53Download video MP4
Download video MP3
Similar videos
-
2:26
allo-hsct and novel drugs for refractory aml
-
2:12
allosct for aml with mds-related features as per the icc and who 2022 classifications
-
1:35
flt3 inhibitor maintenance after allo-sct for aml
-
1:47
individualized machine learning predictions of allosct outcomes in aml: the harmony platform
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
1:28
the role of allogeneic transplantation in patients with aml in the frontline setting
-
2:32
131i-apamistamab-led induction/conditioning prior to allosct in r/r aml: insights from sierra
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
2:55
acl top 500 cts
-
44:31
breaking down evalgen: who validates the validators?
-
3:17
acl top 750
-
3:40
cd4 t-cell reconstitution in allo-hsct settings
-
0:38
optimal time for allo-hsct in aml
-
2:45
the value of axi-cel as a second-line treatment in r/r lbcl
-
1:40
choosing between gene therapy and allosct for scd
-
1:17
the curative potential of allosct in the treatment of hr-mds
-
3:49
the impact of allosct versus blood transfusion & iron chelation on the qol of patients with tdt
-
2:29
epitope editing enables the use of novel immunotherapies for aml
-
1:33
the importance of measurable residual flt3-itd before allosct for aml
-
5:27
is allo-sct still relevant in the immuno-oncology era for hodgkin lymphoma?
-
1:48
do all patients require maintenance therapy following allosct?
-
1:28
assaying flt3 variant allele frequency in aml to determine response to treatment